<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260222068917N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-25</date_registration>
      <primary_sponsor>Superior University, Lahore</primary_sponsor>
      <public_title>A Randomized, Double-Blinded Comparative Study of Pre-Operative Nebulized Dexamethasone and Intravenous Ketorolac Tromethamine for the Prevention of Post-Operative Sore Throat Following General Anesthesia</public_title>
      <acronym>POST: Postoperative Sore Throat</acronym>
      <scientific_title>A Randomized, Double-Blinded Comparative Study of Pre-Operative Nebulized Dexamethasone and Intravenous Ketorolac Tromethamine for the Prevention of Post-Operative Sore Throat Following General Anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/89232</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants in this study were allocated to either the pre-operative nebulized dexamethasone group or the intravenous ketorolac tromethamine group using simple randomization at the level of the individual participant. No stratified randomization was applied, as the study population was homogeneous regarding age, gender, and type of surgery. The random sequence was prepared manually using a table of random numbers, and each participant was assigned a unique sequential number upon enrollment, which was then matched to the pre-prepared random allocation list to determine group assignment. Allocation concealment was maintained using sealed opaque envelopes, which were opened only at the time of intervention to prevent selection bias. No pseudorandomization methods, such as odd/even days, birthdays, or physician choice, were used, Blinding description: In this study, participants are blinded to the type of intervention they receive, as both nebulized dexamethasone and intravenous ketorolac tromethamine are administered in a manner that conceals group allocation. The principal investigator and outcome assessors are also blinded to group assignments to prevent assessment bias when recording postoperative sore throat outcomes. Healthcare providers administering the interventions are aware of the treatment for practical reasons but do not participate in outcome assessment. Data collectors and individuals entering and analyzing the data are blinded to group allocation to maintain objectivity. A sealed opaque envelope system ensures that group allocation remains concealed until the intervention is given. The Data Safety and Monitoring Board (DSMB) and manuscript writers are not involved in treatment administration or outcome assessment and remain unaware of group assignments until study completion. This blinding strategy minimizes bias at multiple levels of the study while maintaining safety and practical feasibility.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Postoperative Sore Throat (POST) following General Anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: Group D – Dexamethasone, Participants receive preoperative nebulized dexamethasone, 15–30 minutes before induction of general anesthesia. Intervention 2: Intervention group 2: Group K – Ketorolac, Participants receive intravenous ketorolac tromethamine, 15–30 minutes before induction of general anesthesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abdul Mabood</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>17 Km Raiwind Road, Lahore, Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 345 8561831</telephone>
        <email>abdulmabood856@gmail.com</email>
        <affiliation>Superior University, Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdul Mabood</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>17 Km Raiwind Road, Lahore, Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 345 8561831</telephone>
        <email>abdulmabood856@gmail.com</email>
        <affiliation>Superior University, Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients   aged   18   –	50 undergoing surgeries that require endotracheal intubation after general anesthesia
ASA Physical status of I–III
Patient giving informed consent.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient known to be allergic to study drugs
Asthmatic or COPD patients
ASA physical status IV – VI
The Patient has a pre-existing sore throat or pain
Surgeries involving the neck, throat, or airway
Upper respiratory tract infection
Patients with a history of renal disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: Group D – Dexamethasone, Participants receive preoperative nebulized dexamethasone, 15–30 minutes before induction of general anesthesia.</i_keyword>
      <i_keyword>Intervention group 2: Group K – Ketorolac, Participants receive intravenous ketorolac tromethamine, 15–30 minutes before induction of general anesthesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence and Severity of Postoperative Sore Throat (POST). Timepoint: Measured at 2, 4, 6, and 12 hours after extubation. Method of measurement: Severity was assessed using the STAT-10 scale, a validated questionnaire for postoperative sore throat.Incidence is recorded as the presence or absence of sore throat at each time point.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>. Timepoint: . Method of measurement: .</sec_outcome>
      <sec_outcome>Secondary outcomes include intubation-related factors (number of attempts and their association with POST severity), cuff pressure categories (≤24 vs &gt;24 cm H₂O), surgery-related factors (type and duration of surgery), endotracheal tube size, postoperative complications (nausea, vomiting, GI irritation, hyperglycemia, delayed wound healing, and others), and requirement for rescue analgesia. Timepoint: Secondary outcomes was measured at 2, 4, 6, and 12 hours after extubation for outcomes related to POST and complications. Method of measurement: The secondary outcomes are measured using a combination of direct observation, structured questionnaires, and patient records. Intubation attempts and endotracheal tube size are recorded intraoperatively from anesthesia notes. Cuff pressure is measured using a manometer at the time of intubation. Surgery type and duration are documented from operative records. Postoperative complications such as nausea, vomiting, GI irritation, hyperglycemia, delayed wound healing, and others are monitored through direct observation and patient self-report. Rescue analgesia requirement is recorded from patient charts and by direct inquiry during the 12-hour postoperative period. Outcome assessors are blinded to group allocation to minimize bias.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Superior University, Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-16</approval_date>
        <contact_name>The Research Ethical Committee, Superior University, Lahore</contact_name>
        <contact_address>17 Km Raiwind Road, Lahore, Pakistan Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
